OSR Holdings Inc OSRH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CEO Statement to Shareholders
-
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
-
CEO Statement to Shareholders
-
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
-
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
-
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
-
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
-
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
Trading Information
- Previous Close Price
- $0.39
- Day Range
- $0.38–0.40
- 52-Week Range
- $0.38–1.79
- Bid/Ask
- $0.39 / $0.40
- Shares Outstanding
- 35.10M
- Market Cap
- $14.15M
- Volume/Avg
- 798,487 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 22
- Website
- https://www.osr-holdings.com
Valuation
|
Metric
|
OSRH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.12 |
Price/Sales | 4.19 |
Price/Cash Flow | — |
Price/Earnings
OSRH
Financial Strength
|
Metric
|
OSRH
|
|---|---|
Quick Ratio | 0.12 |
Current Ratio | 0.16 |
Interest Coverage | −40.25 |
Quick Ratio
OSRH
Profitability
|
Metric
|
OSRH
|
|---|---|
Return on Assets (Normalized) | −10.72% |
Return on Equity (Normalized) | −22.33% |
Return on Invested Capital (Normalized) | −13.54% |
Return on Assets
OSRH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Xzfmtkbyt | Vhskvf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cbcvczzx | Hpypm | $67B | |||
| argenx SE ADR
ARGX
| Qpqfkjyd | Bfn | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yfgtzkyv | Wnlpsbh | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Ngczjzcsz | Jpbfh | $25B | |||
| BioNTech SE ADR
BNTX
| Mqtnsxfvv | Gnvt | $22B | |||
| Incyte Corp
INCY
| Mbhxxjms | Pcwx | $20B | |||
| Moderna Inc
MRNA
| Mkpfvqqs | Lpw | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Xyyqydcnx | Lgw | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Ffpvlwzwk | Bzy | $13B |
United States